I'm sure the FDA would appreciate our comments on their latest ALS Hearing. (Search for FDA ALS hearing and reply to Docket No. FDA-2013-N-0035.) I tried not to be too negative but how optimistic can you be when the average life expectancy for an ALS patient is 3-5 years and it takes 10 years to push a new therapy or drug through all the hoops. Three lifetimes seems like a long time to make patients wait.
I recorded my comment in early /feb when it was first suggested by a poster. After listening to the fantastic testimony I felt my comments were consistent with the testimony and would hopefully alert the FDA to the strong base of support this issue enjoys. I commend your action to revisit the initiatives mentioned at the hearing.
I went to the hearing and the most impressive testimony was by Dr. Jonathan Glass. He was the last speaker in the second section of the webcast. Dr. Segalman, the speaker before him is very interesting, as well. I urge everyone to listen to Dr. Glass and then submit an appropriate comment to the FDA.